K-13

K-13 is a potent and selective small molecule inhibitor of the KRAS G12C mutation, developed by Shanghai Yifeng Biotechnology. It is specifically designed to target the cysteine residue at position 12 of the KRAS protein, which is mutated from glycine to cysteine. This mutation is a common driver in various solid tumors, particularly non-small cell lung cancer (NSCLC) and colorectal cancer. K-13 works by covalently binding to the KRAS G12C protein in its inactive, GDP-bound state, effectively locking it in an "off" position and preventing the activation of downstream signaling cascades such as the RAF-MEK-ERK pathway. This inhibition leads to the suppression of tumor cell proliferation and the induction of apoptosis. K-13 is currently undergoing Phase 1 clinical evaluation for the treatment of advanced solid tumors harboring the KRAS G12C mutation.

Other names

K13K-13K 13